Amgen, UCB explore option of second course of treatment with evenity

This article was originally published here

Amgen and UCB have released results from the fourth year of a Phase 2 study demonstrating the safety and efficacy of a second course of treatment with evenity (romosozumab), an investigational candidate for postmenopausal women with osteoporosis.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply